- Molecular NameAminolevulinic_acid
- SynonymALA; Aminolevulinate; delta-Aminolevulinic acid
- Weight131.131
- Drugbank_IDDB00855
- ACS_NO106-60-5
- Show 3D model
- LogP (experiment)-1.363
- LogP (predicted, AB/LogP v2.0)-2.66
- pkaN/A
- LogD (pH=7, predicted)-5.16
- Solubility (experiment)Soluble
- LogS (predicted, ACD/Labs)(ph=7)-0.23
- LogSw (predicted, AB/LogsW2.0)738.88
- Sw (mg/ml) (predicted, ACD/Labs)58.94
- No.of HBond Donors3
- No.of HBond Acceptors4
- No.of Rotatable Bonds4
- TPSA80.39
- StatusFDA approved
- AdministrationN/A
- PharmacologyIt is used to visualise tumorous tissue in neurosurgical procedures. Studies have shown that the intraoperative use of this guiding method may reduce the tumour residual volume and prolong progression-free survival in patients suffering from this disease. dALA or 5ala is also a photosensitizer for photodynamic therapy.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability55.0
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmFollowing topical administration, synthesis into protoporphyrin IX takes place in situ in the skin.
- Half life0.7h
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A